<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bosentan: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bosentan: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Bosentan: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9254" href="/d/html/9254.html" rel="external">see "Bosentan: Drug information"</a> and <a class="drug drug_patient" data-topicid="11386" href="/d/html/11386.html" rel="external">see "Bosentan: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708663"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Distribution program:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Because of the risks of hepatotoxicity and birth defects, bosentan is available only through a restricted program called the Bosentan REMS Program. Under the Bosentan REMS, prescribers, patients, and pharmacies must enroll in the program.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">In clinical studies, bosentan caused at least a 3-fold upper limit of normal (ULN) elevation of liver aminotransferases (ALT and AST) in about 11% of patients, accompanied by elevated bilirubin in a small number of cases. Because these changes are a marker for potential serious hepatotoxicity, serum aminotransferase levels must be measured prior to initiation of treatment and then monthly. In the postmarketing period, in the setting of close monitoring, rare cases of unexplained hepatic cirrhosis were reported after prolonged (more than 12 months) therapy with bosentan in patients with multiple comorbidities and drug therapies. There have also been reports of liver failure. The contribution of bosentan in these cases could not be excluded.</p>
<p style="text-indent:-2em;margin-left:2em;">In at least 1 case, the initial presentation of hepatotoxicity (after more than 20 months of treatment) included pronounced elevations in aminotransferases and bilirubin levels accompanied by nonspecific symptoms, all of which resolved slowly over time after discontinuation of bosentan. This case reinforces the importance of strict adherence to the monthly monitoring schedule for the duration of treatment and the treatment algorithm, which includes stopping bosentan if a rise of aminotransferase accompanied by signs or symptoms of liver dysfunction occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">Elevations in aminotransferases require close attention. Generally, avoid using bosentan in patients with elevated aminotransferases (greater than 3 times the ULN) at baseline because monitoring for hepatotoxicity may be more difficult. Stop treatment with bosentan if liver aminotransferase elevations are accompanied by clinical symptoms of hepatotoxicity (eg, abdominal pain, fever, jaundice, nausea, unusual lethargy or fatigue, vomiting) or increases in bilirubin 2 times the ULN or greater. There is no experience with the reintroduction of bosentan in these circumstances.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Embryo-fetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Bosentan is likely to cause major birth defects if used by pregnant women based on animal data. Therefore, pregnancy must be excluded before the start of treatment with bosentan. Throughout treatment and for 1 month after stopping bosentan, women of childbearing potential must use 2 reliable methods of contraception unless the patient has an intrauterine device (IUD) or tubal sterilization in which case no other contraception is needed. Hormonal contraceptives, including oral, injectable, transdermal, and implantable contraceptives, should not be used as the sole means of contraception because these may not be effective in patients receiving bosentan. Obtain monthly pregnancy tests.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F142201"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Tracleer</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866107"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Bosentan [DSC];</li>
<li>BIO-Bosentan [DSC];</li>
<li>NAT-Bosentan;</li>
<li>PMS-Bosentan;</li>
<li>SANDOZ Bosentan [DSC];</li>
<li>TARO-Bosentan;</li>
<li>TEVA-Bosentan [DSC];</li>
<li>Tracleer</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F2851892"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Endothelin Receptor Antagonist</span></li></ul></div>
<div class="block don drugH1Div" id="F53462383"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24f4c019-046d-4569-9e10-3ce66e2b730b">Persistent pulmonary hypertension of the newborn</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Persistent pulmonary hypertension of the newborn (PPHN):</b> Limited data available: <b>Note: </b>Guidelines suggest that clinical data do not support use in PPHN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26534956']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26534956'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">GA ≥34 weeks: Oral: Initial: 1 mg/kg/dose twice daily; may increase to 2 mg/kg/dose twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26534956','lexi-content-ref-22076415']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26534956','lexi-content-ref-22076415'])">Ref</a></span>). Improved oxygenation index and oxygen saturation as well as decreased duration of mechanical ventilation and lower neurologic sequelae at 6 months was shown in patients receiving bosentan compared to placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22076415']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22076415'])">Ref</a></span>). In another trial, bosentan was evaluated as an adjunct to nitric oxide; however, no difference in the duration of nitric oxide or time to wean mechanical ventilation was shown when compared to nitric oxide alone; while the bosentan group had a higher severity of illness, this did not impact the study outcomes; there was a trend towards an increased incidence of anemia and edema in the treatment group (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27502103']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27502103'])">Ref</a></span>). Bosentan was also studied as an adjunct with sildenafil; the majority of patients saw improvement within 72 hours of adding bosentan, and supplemental oxygen was weaned and discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33980104']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33980104'])">Ref</a></span>); a reduction in hospital stay and superior reduction in tricuspid regurgitation within 72 hours of initiating treatment was observed in the sildenafil plus bosentan group (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30465360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30465360'])">Ref</a></span>). A case report described successful bosentan use as an adjunct in a more preterm neonate (GA 28 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21380943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21380943'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F2885030"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b6777ad-1508-4cf7-924a-99d10f0a73e1">Pulmonary arterial hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary arterial hypertension: Note:</b> Doses &gt;125 mg twice daily do not provide additional benefit sufficient to offset the increased risk of hepatic injury.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;12 years: Oral: Initial: 1 mg/kg/dose twice daily; increase to a target dose of 2 mg/kg/dose twice daily; maximum dose: 125 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26534956','lexi-content-ref-28213957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26534956','lexi-content-ref-28213957'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26534956']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26534956'])">Ref</a></span>): Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;20 to 40 kg: Initial: 31.25 mg twice daily; increase to a target dose of 62.5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;40 kg: Initial: 62.5 mg twice daily; increase to a target dose of 125 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Alternate dosing: Manufacturer's labeling:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥3 years:</p>
<p style="text-indent:-2em;margin-left:8em;">4 to 8 kg: Oral: 16 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;8 to 16 kg: Oral: 32 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;16 to 24 kg: Oral: 48 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;24 to 40 kg: Oral: 64 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">≤40 kg: Oral: 62.5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;40 kg: Oral: Initial: 62.5 mg twice daily for 4 weeks; increase to target dose of 125 mg twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51083164"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment required. Bosentan is unlikely to be removed by dialysis (due to high molecular weight and extensive plasma protein binding).</p></div>
<div class="block dohp drugH1Div" id="F51083165"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Baseline</i>: Children ≥3 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe impairment and/or baseline transaminase &gt;3 times ULN: Avoid use; systemic exposure is significantly increased in patients with moderate impairment (has not been studied in severe impairment).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during therapy: Adjustment based on transaminase elevation</i>:</p>
<p style="text-indent:-2em;margin-left:4em;">Transaminase elevations accompanied by clinical symptoms of hepatotoxicity (unusual fatigue, nausea, vomiting, abdominal pain, fever, or jaundice) or a serum bilirubin ≥2 times ULN: Children ≥3 years and Adolescents: Discontinue treatment; there is no experience with reintroduction.</p>
<p style="text-indent:-2em;margin-left:4em;">AST/ALT &gt;3 times but ≤5 times ULN:</p>
<p style="text-indent:-2em;margin-left:6em;">Children 3 to ≤12 years and Adolescents ≤40 kg: Confirm with additional test; if confirmed, interrupt treatment with no prior dose reduction. If transaminase levels return to pretreatment values, may reintroduce treatment at the dose used prior to treatment interruption. When reintroducing treatment, recheck transaminases within 3 days and at least every 2 weeks thereafter.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents &gt;40 kg: Confirm with additional test; if confirmed, reduce dose to 62.5 mg twice daily or interrupt treatment and monitor at least every 2 weeks. If transaminase levels return to pretreatment values, may continue or reintroduce treatment at 62.5 mg twice daily, as appropriate. When reintroducing treatment, recheck transaminases within 3 days and at least every 2 weeks thereafter.</p>
<p style="text-indent:-2em;margin-left:4em;">AST/ALT &gt;5 times but ≤8 times ULN:</p>
<p style="text-indent:-2em;margin-left:6em;">Children 3 to ≤12 years and Adolescents ≤40 kg: Confirm with additional test; if confirmed, stop treatment. Monitor transaminase levels at least every 2 weeks. If transaminase levels return to pretreatment values, consider reintroduction at the dose used prior to treatment interruption. When reintroducing treatment, recheck transaminases within 3 days and at least every 2 weeks thereafter.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents &gt;40 kg: Confirm with additional test; if confirmed, stop treatment. Monitor transaminase levels at least every 2 weeks. If transaminase levels return to pretreatment values, may reintroduce treatment at 62.5 mg twice daily, as appropriate. When reintroducing treatment, recheck transaminases within 3 days and at least every 2 weeks thereafter.</p>
<p style="text-indent:-2em;margin-left:4em;">AST/ALT &gt;8 times ULN: Children ≥3 years and Adolescents: Stop treatment and do not reintroduce.</p></div>
<div class="block doa drugH1Div" id="F142205"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9254" href="/d/html/9254.html" rel="external">see "Bosentan: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b6777ad-1508-4cf7-924a-99d10f0a73e1">Pulmonary arterial hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary arterial hypertension:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult a pulmonary arterial hypertension specialist for all management decisions; choice of therapy is dependent on etiology, risk stratification, and cardiopulmonary comorbidities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30660783','lexi-content-ref-36017548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30660783','lexi-content-ref-36017548'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;40 kg: <b>Oral: </b>Initial and maintenance: 62.5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">≥40 kg: <b>Oral:</b> Initial: 62.5 mg twice daily; after ~4 weeks, may increase to a maximum dose of 125 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> When discontinuing treatment, consider a reduction in dosage to 62.5 mg twice daily for 3 to 7 days to avoid clinical deterioration, then stop treatment.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="60fed34f-6947-4fa9-b704-cdf377f6c3a0">Digital ulcers in systemic sclerosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Digital ulcers in systemic sclerosis (off-label use): </b>Oral: 62.5 mg twice daily for 4 weeks followed by an increase to a maintenance dose of 125 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15593188','lexi-content-ref-20805294']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15593188','lexi-content-ref-20805294'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1255d8f6-fd68-4bc5-82df-4c611d943ebf">Raynaud phenomenon in systemic sclerosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Raynaud phenomenon in systemic sclerosis (off-label use): </b>Oral: 62.5 mg twice daily for 4 weeks followed by an increase to a maintenance dose of 125 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21244767','lexi-content-ref-17881663']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21244767','lexi-content-ref-17881663'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991070"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary. Bosentan is unlikely to be removed by dialysis (due to high molecular weight and extensive plasma protein binding).  </p></div>
<div class="block doha drugH1Div" id="F50988331"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment at treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe impairment (Child-Pugh class B and C) and/or baseline transaminase &gt;3 times ULN: Avoid use; systemic exposure is significantly increased in patients with moderate impairment (has not been studied in severe impairment).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment: Modification based on transaminase elevation: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Transaminase elevations accompanied by clinical symptoms of hepatotoxicity (unusual fatigue, nausea, vomiting, abdominal pain, fever, or jaundice) or a serum bilirubin ≥2 times ULN: Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">AST/ALT &gt;3 times but ≤5 times ULN: &gt;40 kg: Confirm with additional test; if confirmed, reduce dose to 62.5 mg twice daily or interrupt treatment and monitor at least every 2 weeks. If transaminase levels return to pretreatment values, may continue or reintroduce treatment (at the starting dose), as appropriate. When reintroducing treatment, recheck transaminases within 3 days and at least every 2 weeks thereafter.</p>
<p style="text-indent:-2em;margin-left:4em;">AST/ALT &gt;5 times but ≤8 times ULN: &gt;40 kg: Confirm with additional test; if confirmed, stop treatment. Monitor transaminase levels at least every 2 weeks. If transaminase levels return to pretreatment values, may reintroduce treatment (at the starting dose) as appropriate. When reintroducing treatment, recheck transaminases within 3 days and at least every 2 weeks thereafter.</p>
<p style="text-indent:-2em;margin-left:4em;">AST/ALT &gt;8 times ULN: Stop treatment and do not reintroduce.</p></div>
<div class="block adr drugH1Div" id="F142172"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (≤11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum ALT (≥3 times ULN: ≤12%; 8 times ULN: ≤2%; dose-related), increased serum AST (≥3 times ULN: ≤12%; 8 times ULN: ≤2%; dose-related)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory tract infection (22%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (5%), syncope (5%), flushing (4%), hypotension (4%), palpitations (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Fluid retention (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sinusitis (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, DRESS syndrome, hepatic cirrhosis (prolonged therapy), hepatic failure (rare), hypersensitivity reaction, jaundice, leukopenia, nasal congestion, neutropenia, peripheral edema, severe anemia, skin rash, thrombocytopenia</p></div>
<div class="block coi drugH1Div" id="F142186"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to bosentan or any component of the formulation; concurrent use of cyclosporine or glyburide; women who are or may become pregnant.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Moderate to severe hepatic impairment (eg, ALT or AST &gt;3 times ULN, particularly when total bilirubin &gt;2 times ULN).</p></div>
<div class="block war drugH1Div" id="F142170"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid retention/peripheral edema: Development of peripheral edema due to treatment and/or disease state (pulmonary arterial hypertension) may occur. There have also been postmarketing reports of fluid retention requiring treatment (eg, diuretics, fluid management, hospitalization) for heart failure. If clinically significant fluid retention develops (with or without weight gain), further evaluation is necessary to determine cause and appropriate treatment or discontinuation of therapy. Use with caution in patients with underlying heart failure due to potential complications from fluid retention. In a scientific statement from the American Heart Association, bosentan has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: Dose-related decreases in hematocrit/hemoglobin may be observed, usually within the first few weeks of therapy with subsequent stabilization of levels by 4 to 12 weeks of treatment. Monitor hemoglobin prior to treatment initiation, after 1 and 3 months, and every 3 months thereafter. Significant decreases in hemoglobin require further evaluation to determine the cause and specific management.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity:<b> [US Boxed Warning]: Bosentan is associated with transaminase elevations (ALT or AST ≥3 times ULN), and in a small number of cases may occur with elevations in bilirubin. Monitor transaminases at baseline then monthly thereafter. Adjust dosage if elevations in liver enzymes occur without symptoms of hepatic injury or elevated bilirubin. In the postmarketing surveillance (with close monitoring), there have been rare cases of unexplained hepatic cirrhosis after prolonged therapy (&gt;12 months) in patients with multiple comorbidities and drug therapies. There have also been cases of hepatic failure. Treatment should be stopped in patients who develop elevated transaminases either in combination with symptoms of hepatic injury (unusual fatigue, jaundice, nausea, vomiting, abdominal pain, and/or fever) or elevated bilirubin (≥2 times ULN); safety of reintroduction is unknown. Avoid use in patients with baseline serum transaminases &gt;3 times ULN at baseline (monitoring for hepatotoxicity may be more difficult) or moderate to severe hepatic impairment.</b> The combination of hepatocellular injury (transaminase elevations &gt;3 times ULN) and bilirubin increased ≥2 times ULN are a marker for potential serious hepatotoxicity. Transaminase elevations are dose dependent, generally asymptomatic, occur both early and late in therapy, progress slowly, and are usually reversible after treatment interruption or discontinuation. Transaminase elevations may also spontaneously reverse while continuing bosentan treatment. Consider the benefits of treatment versus the risk of hepatotoxicity when initiating therapy in patients with WHO Class II symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), anaphylaxis, rash and angioedema have been observed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary veno-occlusive disease: If signs of pulmonary edema occur, consider possibility of pulmonary veno-occlusive disease; may require discontinuation of bosentan.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pregnancy: <b>[US Boxed Warning]: Bosentan is likely to cause major birth defects if used by pregnant women based on animal data. Therefore, pregnancy must be excluded before the start of treatment with bosentan. Throughout treatment and for 1 month after stopping bosentan, women of childbearing potential must use 2 reliable methods of contraception unless the patient has an intrauterine device (IUD) or tubal sterilization in which case no other contraception is needed. Hormonal contraceptives, including oral, injectable, transdermal, and implantable contraceptives, should not be used as the sole means of contraception because these may not be effective in patients receiving bosentan. Obtain monthly pregnancy tests.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aspartame: Some products may contain aspartame, which is metabolized to phenylalanine and must be avoided (or used with caution) in patients with phenylketonuria.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• REMS program:<b> [US Boxed Warning]: Because of the risks of hepatotoxicity and birth defects, bosentan is only available through the Bosentan</b>
<b> REMS Program. Patients, prescribers, and pharmacies must enroll with the program.</b> Call 1-866-359-2612 or visit www.BosentanREMSProgram.com for more information.</p></div>
<div class="block foc drugH1Div" id="F142181"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tracleer: 62.5 mg, 125 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 62.5 mg, 125 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Soluble, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tracleer: 32 mg [scored; contains aspartame]</p></div>
<div class="block geq drugH1Div" id="F142166"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F23613382"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet,Dispersible</b> (Tracleer Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">32 mg (per each): $244.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Bosentan Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">62.5 mg (per each): $209.14 - $221.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (per each): $209.14 - $221.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Tracleer Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">62.5 mg (per each): $244.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (per each): $244.03</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866108"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tracleer: 62.5 mg, 125 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 62.5 mg, 125 mg</p></div>
<div class="block exp drugH1Div" id="F2932641"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Tablets for oral suspension<b> (32 mg </b>dispersible tablets) are commercially available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>6.25 mg/mL Oral Suspension</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b> Note: </b>The following personal protective equipment should be used when preparing bosentan oral suspension: Double gloving, protective gown and a respiratory mask if preparation does not occur in a fume hood.</p>
<p style="text-indent:-2em;margin-left:2em;">A 6.25 mg/mL oral suspension may be made from nondispersable tablets and a 1:1 mixture of FlavorPlus and FlavorSweet. Crush three 62.5 mg tablets in a ceramic mortar. Add a small amount of glycerin and reduce to a fine powder. Add ~10 mL of the vehicle and triturate; add an additional 10 mL of vehicle and transfer to a calibrated amber bottle. Rinse the mortar and pestle with 10 mL vehicle and add to bottle to bring the final volume to 30 mL. Stable for 30 days when stored in a amber bottle at room temperature or under refrigeration.</p>
<div class="reference">
<a name="27303093"></a>Malik A, Gorman G, Coward L, Arnold JJ. Stability of an extemporaneously compounded oral suspension of bosentan. <i>Hosp Pharm</i>. 2016;51(5):389-95. doi: 10.1310/hpj5105-389.<span class="pubmed-id">27303093</span></div>
</div>
<div class="block admp drugH1Div" id="F52612320"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Bosentan has been classified as a hazardous substance by NIOSH due to its associated risk of birth defects; double gloving, a protective gown, and preparation in a controlled device is recommended when splitting, crushing, or handling broken tablets; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration or handling of bodily fluids/waste (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Niosh.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Niosh.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered without regard to meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets for oral suspension (dispersible tablets): Disperse in a minimal amount of water immediately before administration. The 32 mg dispersible tablet may be divided into halves; do not break into quarters.</p></div>
<div class="block adm drugH1Div" id="F142183"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets for oral suspension (dispersible tablets): Disperse in a minimal amount of water immediately before administration. The 32 mg dispersible tablet may be divided into halves; do not break into quarters.</p></div>
<div class="block hazard drugH1Div" id="F49130909"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F142196"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store film-coated and dispersible tablets at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Store divided dispersible tablet pieces in the opened blister for up to 7 days.</p></div>
<div class="block meg drugH1Div" id="F7874386"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F021290s039%2C209279s005lbl.pdf%23page%3D30&amp;token=0D3XxjV3UU6aPLUJJsd5fYMWuf2F2tgU%2F98pY0a5icFt%2FSepsb3wpwBxLm7SqCDBJLlDMH8tf%2FQnVqvUUxBSi4T6M1QyzMlmopBUTwVKi91a56kodmQOsa4Sx4kYR3Nt&amp;TOPIC_ID=13087" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021290s039,209279s005lbl.pdf#page=30</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53565717"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of pulmonary arterial hypertension (PAH) [WHO Group I] in patients with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), resulting in an improvement in exercise ability (FDA approved in pediatric patients ≥3 years); treatment of PAH (WHO Group 1) in patients with WHO Functional Class II, III, or IV symptoms to improve exercise capacity and decrease the rate of clinical deterioration (FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F6053349"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tracleer may be confused with TriCor</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F142217"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (minor), CYP3A4 (minor), OATP1B1/1B3 (SLCO1B1/1B3); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> CYP2C9 (weak), CYP3A4 (moderate)</p></div>
<div class="block dri drugH1Div" id="F142174"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Abemaciclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Abiraterone Acetate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Acalabrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adagrasib: May increase the serum concentration of Bosentan.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ALfentanil.  Management: If concomitant use of alfentanil and moderate CYP3A4 inducers is necessary, consider dosage increase of alfentanil until stable drug effects are achieved. Monitor patients for signs of opioid withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Antihepaciviral Combination Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apremilast: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Apremilast. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Aprepitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ARIPiprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be decreased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Artemether and Lumefantrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: Bosentan may decrease the serum concentration of Atazanavir. Atazanavir may increase the serum concentration of Bosentan.  Management: Concurrent use of unboosted atazanavir (without ritonavir or cobicistat) and bosentan is not recommended. Bosentan dose adjustments and increased monitoring are recommended when used together with boosted atazanavir. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avacopan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avanafil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avapritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Axitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bedaquiline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Belumosudil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Benzhydrocodone. Specifically, the serum concentrations of hydrocodone may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bosutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Brexpiprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with moderate CYP3A4 inducers when possible. If combined, increase the daily dose of brigatinib in 30 mg increments after 7 days of treatment with the current brigatinib dose, up to maximum of twice the dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of BusPIRone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Capivasertib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capmatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Capmatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cariprazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ceritinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: Bosentan may increase serum concentrations of the active metabolite(s) of Clarithromycin. Specifically, bosentan may increase concentrations of 14-hydroxyclarithromycin. Bosentan may decrease the serum concentration of Clarithromycin. Clarithromycin may increase the serum concentration of Bosentan.  Management: Consider alternative antimicrobial if possible. The clinical activity of clarithromycin may be altered, and increased bosentan toxicity may be expected.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May increase the serum concentration of Bosentan. Management: Dose adjustment of bosentan and increased monitoring for bosentan toxicities is necessary when these agents are combined. See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Copanlisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Crizotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Bosentan.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Daclatasvir.  Management: Increase the daclatasvir dose to 90 mg once daily if used with a moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dapsone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Daridorexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasabuvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dasabuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: CYP3A4 Inducers (Moderate) may increase the serum concentration of Dasatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Delavirdine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of DexAMETHasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DilTIAZem: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DilTIAZem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Disopyramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doravirine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Doravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dronedarone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Duvelisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Duvelisib.  Management: Avoid if possible. If used, on day 12 of combination increase duvelisib from 25 mg twice daily to 40 mg twice daily or from 15 mg twice daily to 25 mg twice daily. Resume prior duvelisib dose 14 days after stopping moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dydrogesterone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dydrogesterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Efavirenz. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elbasvir and Grazoprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Eliglustat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elvitegravir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of Encorafenib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Entrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enzalutamide: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Enzalutamide. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Enzalutamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Erdafitinib.  Management: Dose modifications of erdafitinib may be required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Erlotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Exemestane. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fedratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Felodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Finerenone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: May increase the serum concentration of Bosentan.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fosaprepitant. Specifically, CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite aprepitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosnetupitant: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fosnetupitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostamatinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fostamatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fruquintinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fruquintinib.  Management: Avoid this combination when possible. If combined, continue the same fruquintinib dose, but monitor for reduced fruquintinib efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganaxolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ganaxolone.  Management: Avoid concomitant use of ganaxolone and moderate CYP3A4 inducers whenever possible. If combined, consider increasing the dose of ganaxolone, but do not exceed the maximum recommended daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gefitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemfibrozil: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemigliptin: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Gemigliptin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gemigliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gepirone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Glasdegib.  Management: Avoid use of glasdegib and moderate CYP3A4 inducers whenever possible. If combined, increase glasdegib dose from 100 mg daily to 200 mg daily or from 50 mg daily to 100 mg daily. Resume previous glasdegib dose 7 days after discontinuation of the inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GlyBURIDE: May enhance the hepatotoxic effect of Bosentan. GlyBURIDE may decrease the serum concentration of Bosentan. Bosentan may decrease the serum concentration of GlyBURIDE.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of GuanFACINE.  Management: Increase extended-release guanfacine dose by up to double when initiating guanfacine in patients taking CYP3A4 inducers or if initiating a CYP3A4 inducer in a patient already taking extended-release guanfacine. Monitor for reduced guanfacine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a moderate CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrexafungerp: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ibrexafungerp. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ibrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Idelalisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Idelalisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Imatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inducers (Moderate) may decrease isavuconazole serum concentrations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Istradefylline: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Istradefylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Itraconazole. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Itraconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixazomib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ixazomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketamine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ketamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ketoconazole (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Larotrectinib.  Management: Double the larotrectinib dose if used together with a moderate CYP3A4 inducer. Following discontinuation of the moderate CYP3A4 inducer, resume the previous dose of larotrectinib after a period of 3 to 5 times the inducer's half-life.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin with moderate CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin (Intravenous): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lefamulin (Intravenous).  Management: Avoid concomitant use of lefamulin (intravenous) with moderate CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lenacapavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Leniolisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: Bosentan may decrease the serum concentration of Letermovir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levoketoconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LinaGLIPtin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of LinaGLIPtin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorlatinib: CYP3A4 Inducers (Moderate) may enhance the hepatotoxic effect of Lorlatinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lorlatinib.  Management: Avoid use of lorlatinib with moderate CYP3A4 inducers. If such a combination must be used, increase lorlatinib to 125 mg daily. Monitor for reduced lorlatinib efficacy and consider closer monitoring of AST, ALT, and bilirubin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lumacaftor and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lumateperone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lurasidone.  Management: Monitor for decreased lurasidone effects if combined with moderate CYP3A4 inducers and consider increasing the lurasidone dose if coadministered with a moderate CYP3A4 inducer for 7 or more days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Bosentan may diminish the diagnostic effect of Macimorelin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Macitentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice/day, but only if not receiving a strong CYP3A4 inhibitor. Not recommended for pediatric patients not also receiving a strong CYP3A4 inhibitor. Contraindicated in patients with CrCl less than 30 mL/min.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maribavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Maribavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mefloquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Meperidine. Specifically, concentrations of normeperidine, the CNS stimulating metabolite, may be increased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of MethylPREDNISolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mianserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Midostaurin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May increase the serum concentration of Bosentan.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mitapivat.  Management: Consider alternatives to this combination when possible. If combined, monitor hemoglobin and titrate mitapivat beyond 50 mg twice daily, if needed, but do not exceed doses of 100 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Mobocertinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mobocertinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netupitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Netupitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nevirapine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nevirapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of NIFEdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nilotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilvadipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nilvadipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Bosentan. Management: Consider alternative COVID-19 treatments in patients taking bosentan. If nirmatrelvir and ritonavir must be used, discontinue bosentan at least 36 hours before initiation of nirmatrelvir and ritonavir. Monitor for increased bosentan toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olaparib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olutasidenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olutasidenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Omaveloxolone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Osimertinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of OxyCODONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Palbociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Palovarotene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PAZOPanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pemigatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Perampanel.  Management: Increase perampanel starting dose to 4 mg/day if used with moderate CYP3A4 inducers. Increase perampanel dose by 2 mg/day no more than once weekly based on response and tolerability. Dose adjustments may be needed if the inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: Bosentan may decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Phosphodiesterase 5 Inhibitors may increase the serum concentration of Bosentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pimavanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Piperaquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pirtobrutinib.  Management: Avoid concomitant use if possible. If combined, if the current pirtobrutinib dose is 200 mg once daily, increase to 300 mg once daily. If current pirtobrutinib dose is 50 mg or 100 mg once daily, increase the dose by 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PONATinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, increase pralsetinib dose from 400 mg daily to 600 mg daily; from 300 mg daily to 500 mg daily; and from 200 mg daily to 300 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Praziquantel.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for reduced praziquantel efficacy. If possible, stop the moderate CYP3A4 inducer 2 to 4 weeks before praziquantel initiation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PrednisoLONE (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PredniSONE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pretomanid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protease Inhibitors: May increase the serum concentration of Bosentan. Management: Dose adjustment of bosentan and increased monitoring for bosentan toxicities is necessary when these agents are combined. See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of QUEtiapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Quizartinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Regorafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ribociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Bosentan. Following the initial week of concurrent rifampin, this effect is most likely. RifAMPin may increase the serum concentration of Bosentan. This effect is most likely to be observed within the initial few days of concurrent therapy (and may be greatest immediately following initiation of the combination).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rilpivirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rimegepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ripretinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ripretinib.  Management: Avoid this combination if possible. If concomitant use is required, increase ripretinib to 150 mg twice daily. Decrease ripretinib to 150 mg once daily 14 days after stopping a moderate CYP3A4 inducer. Monitor patients for ripretinib response and toxicity<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of RisperiDONE. CYP3A4 Inducers (Moderate) may decrease the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ritlecitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast (Systemic): CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Roflumilast (Systemic). CYP3A4 Inducers (Moderate) may decrease the serum concentration of Roflumilast (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rolapitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rolapitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Samidorphan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Selpercatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Selumetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertraline: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sertraline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: Bosentan may decrease the serum concentration of Sildenafil. Sildenafil may increase the serum concentration of Bosentan.  Management: When sildenafil is used for treatment of pulmonary arterial hypertension (PAH), coadministration of sildenafil and bosentan is not recommended. Otherwise, monitor for reduced sildenafil efficacy if combined with bosentan.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SORAfenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sotorasib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May enhance the adverse/toxic effect of Endothelin Receptor Antagonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SUFentanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SUNItinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Suvorexant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tadalafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tamoxifen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tazemetostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, sirolimus concentrations may be decreased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Temsirolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tetrahydrocannabinol and Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tezacaftor and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Thiotepa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tivozanib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tivozanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tofacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tolvaptan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Toremifene. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Toremifene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of TraZODone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trofinetide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors). Management: Avoid concurrent use with OATP1B1/1B3 substrates for which small changes in exposure may be associated with serious toxicities. Monitor for evidence of an altered response to any OATP1B1/1B3 substrate if used together with trofinetide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tucatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tucatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Upadacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vandetanib: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Vandetanib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vandetanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vemurafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Venetoclax. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Verapamil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Bosentan may decrease the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voclosporin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vonoprazan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vonoprazan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voriconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vortioxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxelotor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voxelotor.  Management: Avoid concomitant use of voxelotor and moderate CYP3A4 inducers. If unavoidable, increase the voxelotor dose to 2,000 mg once daily. For children ages 4 to less than 12 years, weight-based dose adjustments are required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zaleplon: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zaleplon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zanubrutinib.  Management: Avoid this combination if possible. If coadministration of zanubrutinib and a moderate CYP3A4 inducer is required, increase the zanubrutinib dose to 320 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zuranolone. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F142197"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Bioavailability of bosentan is not affected by food.</p></div>
<div class="block rep_considerations drugH1Div" id="F49095592"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Bosentan is contraindicated in females who may become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>[US Boxed Warning]: Pregnancy must be excluded before the start of treatment with bosentan. Throughout treatment and for 1 month after stopping bosentan, women of childbearing potential must use two reliable methods of contraception unless the patient has an intrauterine device (IUD) or tubal sterilization in which case no other contraception is needed. Hormonal contraceptives, including oral, injectable, transdermal, and implantable contraceptives, should not be used as the sole means of contraception because these may not be effective in patients receiving bosentan. Obtain monthly pregnancy tests.</b> When a hormonal or barrier contraceptive is used, one additional method of contraception is still needed if a male partner has had a vasectomy. A missed menses or suspected pregnancy should be reported to a health care provider and prompt immediate pregnancy testing.</p>
<p style="text-indent:0em;margin-top:2em;">Decreased sperm counts and adverse effects on spermatogenesis have been observed in men during treatment; fertility may be impaired. It is not known if effects on fertility are reversible.</p></div>
<div class="block pri drugH1Div" id="F142187"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Bosentan is contraindicated in females who are pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>[US Boxed Warning]: </b>
<b>Bosentan is likely to cause major birth defects if used by pregnant women based on animal data. </b></p>
<p style="text-indent:0em;margin-top:2em;">Women with pulmonary arterial hypertension (PAH) are encouraged to avoid pregnancy (McLaughlin 2009; Taichman 2014).</p></div>
<div class="block mopp drugH1Div" id="F53565705"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Serum transaminase (AST and ALT) and bilirubin (prior to treatment initiation and monthly thereafter, or more frequently if clinically necessary [eg, every 2 weeks following transaminase elevations and 3 days after reintroducing therapy if withheld due to transaminase elevations]). Hemoglobin and hematocrit (at baseline, after 1 month and 3 months of treatment, then every 3 months thereafter). Monitor for clinical signs and symptoms of liver injury (eg, abdominal pain, fatigue, fever, jaundice, nausea, vomiting) and fluid retention.</p>
<p style="text-indent:-2em;margin-left:2em;">Pregnancy test in patients of childbearing potential (prior to the initiation of therapy, monthly thereafter, and 1 month after stopping therapy).</p></div>
<div class="block pha drugH1Div" id="F142169"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Endothelin receptor antagonist that blocks endothelin receptors on endothelium and vascular smooth muscle (stimulation of these receptors is associated with vasoconstriction). Bosentan blocks both ET<sub>A</sub> and ET<sub>B</sub> receptors, with a slightly higher affinity for the A subtype.</p></div>
<div class="block phk drugH1Div" id="F142185"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~18 L (does not distribute into RBCs)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: &gt;98%, primarily to albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP2C9 and 3A4 to three metabolites (one active, contributing ~10% to 20% pharmacologic activity); steady-state plasma concentrations are 50% to 65% of those attained after single dose (most likely due to autoinduction of liver enzymes); steady-state is attained within 3 to 5 days</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~50%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~5 hours; prolonged with heart failure, possibly in PAH</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 3 to 5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (as metabolites); urine (&lt;3% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51153977"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In patients with severe renal impairment (CrCl 15 to 30 mL/minute), concentrations of the 3 metabolites may increase 2-fold, although it is not clinically significant.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Exposure to bosentan may be significantly increased in hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Exposure to bosentan reaches a plateau at lower doses in pediatric patients than in adults, and doses &gt;2 mg/kg twice daily do not increase the exposure to bosentan in pediatric patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038542"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Bosentor | Ecole | Tracleer</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Amalox | Bosentac | Bosental | Endotan | Hasnub | Letib | Masican | Talosin | Tracleer | Trasentan | Usenta</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Bosentan accord | Bosentan dr reddys | Stayveer | Tracleer</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Bosentan apotex | Bosentan cipla | Bosentan dr reddys | Bosentan gh | Bosentan mylan | Bosentan rbx | Bosentan sandoz | Bosleer | Tracleer</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Pulmoten</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Bosentan ab | Bosentan accord | Bosentan sandoz | Bosentan teva | Tracleer</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Bosentan accord | Ipertazin | Stayveer | Tracleer</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bosentana | Hagivan | Tracleer</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Bosentan mepha | Tracleer</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Babyx | Tracleer | Usenta</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Tracleer</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bioxentan | Bolyston | Bontelin | Bosentas | Filipika | Monotan | Paglix | Pulmonell | Purosentan | Safebo | Sulmida | Tabosen | Tensiopril | Tracleer | Usenta</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Bosentan abdi | Bosentan accord | Bosentan avmc | Bosentan ebewe | Bosentan mylan | Bosentan pharmascience international | Bosentan sandoz | Bosentan welding | Stayveer | Tracleer</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bosentan 1a pharma | Bosentan accord | Bosentan aliud | Bosentan basics | Bosentan beta | Bosentan cipla | Bosentan Heumann | Bosentan hexal | Bosentan mylan | Bosentan puren | Bosentan ratiopharm | Bosentan teva | Bosentan zentiva | Tracleer</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Endotan | Tracleer | Usenta</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bosentan accord | Bosentan Norameda | Tracleer</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Bosentadin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bosentan accord | Bosentan aurovitas | Bosentan cipla | Bosentan dr reddys | Bosentan kern pharma | Bosentan mylan | Bosentan normon | Bosentan sandoz | Bosentan sun | Bosentan teva | Stayveer | Tracleer</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Bosentan msn</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bosentan accord | Bosentan actavis | Bosentan orion | Stayveer | Tracleer</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Bosentan accord | Bosentan arrow | Bosentan biogaran | Bosentan eg | Bosentan mylan | Bosentan ohre pharma | Bosentan teva | Tracleer</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Bosentan | Bosentan accord | Bosentan cipla | Stayveer | Tracleer</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Bosentan mylan | Klimurtan | Sentoba | Stayveer | Tracleer | Vradem</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Pulmonat | Tracleer</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Phan | Tracleer</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ipertazin | Stayveer | Trocordis</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Tracleer</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Tracleer</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bosenat | Bosentas | Bozetan | Lupibose | Pulvance</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Bosentan</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bosentan accord | Bosentan aurobindo | Bosentan doc generici | Bosentan Medac | Bosentan mylan | Bosentan sandoz | Bosentan sun | Bosentan teva | Bosentan zentiva | Tracleer</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Tracleer</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bosentan dsep | Bosentan jg | Bosentan kn | Bosentan mochida | Bosentan pfizer | Bosentan sawai | Bosentan tanabe | Tracleer</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Bosetan | Pulmofirst</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Canabosen | Pahsentan | Trasista</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Tracleer</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Pms bosentan | Tracleer</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Bosentan accord | Bosentan cipla | Bosentan Norameda | Bosentan sandoz | Tracleer</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Bosentan Norameda | Bosentan sandoz | Tracleer</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Gozzen | Lunastra | Sensord | Tracleer | Zuxtana</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Bosentas | Proart</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Bosentan accord | Bosentan aurobindo | Bosentan sandoz | Stayveer | Tracleer</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bosentan accord | Bosentan aurobindo | Bosentan cipla | Bosentan sandoz | Stayveer | Tracleer</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Bosentan dr reddys | Mylan bosentan | Tracleer</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Canabosen | Pulmofirst | Tracleer | Usenta</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Bosecard | Bosent | Bosentan | Bosmon | Bosotec | Bozpah | Bsantan</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Bopaho | Bosentan celon | Bosentan sandoz | Stayveer | Tracleer</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Tracleer</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bosentano Accord | Bosentano aurobindo | Bosentano mylan | Bosentano sandoz | Bosentano teva | Bosentano zentiva | Tracleer</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Bosentan Imedic | Bosentan prosalud | Bosentan vmg | Usenta</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Gonista | Tracleer</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Bopaho | Bosentan terapia | Bosentan zentiva | Stayveer | Tracleer</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Bosenex | Bosentan | Bozentan canon | Tracleer | Tracleer dt | Vasenex</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Bosentor | Pms bosentan | Tracleer</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bosentan accord | Bosentan actavis | Bosentan aurobindo | Bosentan sandoz | Stayveer | Tracleer</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Bopaho | Bosentan Norameda | Stayveer | Tracleer</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Bosentan accord | Bosentan mylan | Bosentan sandoz | Stayveer | Tracleer</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Silkay | Tracleer</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Pms bosentan | Tracleer</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Diamond | Tracleer | Tractan | Zepahex</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Tracleer</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Bosentan accord | Bosentan sandoz</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Pulmofirst</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">C.B.A.</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Agbosen | Trasenib</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26534956">
<a name="26534956"></a>Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: Guidelines from the American Heart Association and American Thoracic Society [published correction appears in <i>Circulation</i>. 2016;133(4):e368]. <i>Circulation</i>. 2015;132(21):2037-2099.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/26534956/pubmed" id="26534956" target="_blank">26534956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16098439">
<a name="16098439"></a>Adatia I, "Improving the Outcome of Childhood Pulmonary Arterial Hypertension: The Effect of Bosentan in the Setting of a Dedicated Pulmonary Hypertension Clinic," <i>J Am Coll Cardiol</i>, 2005, 46(4):705-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/16098439/pubmed" id="16098439" target="_blank">16098439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16980516">
<a name="16980516"></a>Apostolopoulou SC, Manginas A, Cokkinos DV, et al, "Long-Term Oral Bosentan Treatment in Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease: A 2-Year Study," <i>Heart</i>, 2007, 93(3):350-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/16980516/pubmed" id="16980516" target="_blank">16980516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12709727">
<a name="12709727"></a>Barst RJ, Ivy D, Dingemanse J, et al, “Pharmacokinetics, Safety, and Efficacy of Bosentan in Pediatric Patients With Pulmonary Arterial Hypertension,” <i>Clin Pharmacol Ther</i>, 2003, 73(4):372-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/12709727/pubmed" id="12709727" target="_blank">12709727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19356006">
<a name="19356006"></a>Beghetti M, "Bosentan in Pediatric Patients With Pulmonary Arterial Hypertension," <i>Curr Vasc Pharmacol</i>, 2009, 7(2):225-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/19356006/pubmed" id="19356006" target="_blank">19356006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16919006">
<a name="16919006"></a>Beghetti M, "Current Treatment Options in Children With Pulmonary Arterial Hypertension and Experiences With Oral Bosentan," <i>Eur J Clin Invest</i>, 2006, 36(Suppl 3):16-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/16919006/pubmed" id="16919006" target="_blank">16919006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20002090">
<a name="20002090"></a>Beghetti M, Haworth SG, Bonnet D, et al, "Pharmacokinetic and Clinical Profile of a Novel Formulation of Bosentan in Children With Pulmonary Arterial Hypertension: The FUTURE-1 Study," <i>Br J Clin Pharmacol</i>, 2009a, 68(6):948-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/20002090/pubmed" id="20002090" target="_blank">20002090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18414142">
<a name="18414142"></a>Beghetti M, Hoeper MM, Kiely DG, et al, "Safety Experience With Bosentan in 146 Children 2-11 Years Old With Pulmonary Arterial Hypertension: Results From the European Postmarketing Surveillance Program," <i>Pediatr Res</i>, 2008, 64(2):200-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/18414142/pubmed" id="18414142" target="_blank">18414142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28213957">
<a name="28213957"></a>Berger RMF, Gehin M, Beghetti M, et al. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. <i>Br J Clin Pharmacol</i>. 2017;83(8):1734-1744.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/28213957/pubmed" id="28213957" target="_blank">28213957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034342">
<a name="20034342"></a>Carter NJ and Keating GM, "Bosentan: In Pediatric Patients With Pulmonary Arterial Hypertension," <i>Paediatr Drugs</i>, 2010, 12(1):63-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/20034342/pubmed" id="20034342" target="_blank">20034342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30465360">
<a name="30465360"></a>Fatima N, Arshad S, Quddusi AI, Rehman A, Nadeem A, Iqbal I. Comparison of the efficacy of sildenafil alone versus sildenafil plus bosentan in newborns with persistent pulmonary hypertension. <i>J Ayub Med Coll Abbottabad</i>. 2018;30(3):333-336.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/30465360/pubmed" id="30465360" target="_blank">30465360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16142516">
<a name="16142516"></a>Gilbert N, Luther YC, Miera O, et al, "Initial Experience With Bosentan (Tracleer®) as Treatment for Pulmonary Arterial Hypertension (PAH) Due to Congenital Heart Disease in Infants and Young Children," <i>Z Kardiol</i>, 2005, 94(9):570-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/16142516/pubmed" id="16142516" target="_blank">16142516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21244767">
<a name="21244767"></a>Giordano N, Puccetti L, Papakostas P, et al. Bosentan treatment for Raynaud's phenomenon and skin fibrosis in patients with systemic sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study. <i>Int J Immunopathol Pharmacol</i>. 2010;23(4):1185-1194.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/21244767/pubmed" id="21244767" target="_blank">21244767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17881663">
<a name="17881663"></a>Hettema ME, Zhang D, Bootsma H, Kallenberg CG. Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis.<i>Ann Rheum Dis</i>. 2007;66(10):1398-1399.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/17881663/pubmed" id="17881663" target="_blank">17881663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017548">
<a name="36017548"></a>Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. <i>Eur Heart J.</i> 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/36017548/pubmed" id="36017548" target="_blank">36017548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15050507">
<a name="15050507"></a>Ivy DD, Doran A, Claussen L, Bingaman D, Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. <i>Am J Cardiol.</i> 2004;93(7):943-946.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/15050507/pubmed" id="15050507" target="_blank">15050507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21029834">
<a name="21029834"></a>Ivy DD, Rosenzweig EB, Lemarié JC, et al, "Long-Term Outcomes in Children With Pulmonary Arterial Hypertension Treated With Bosentan in Real-World Clinical Settings," <i>Am J Cardiol</i>, 2010, 106(9):1332-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/21029834/pubmed" id="21029834" target="_blank">21029834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33980104">
<a name="33980104"></a>Kamran A, Rafiq N, Khalid A, et al. Effectiveness of oral sildenafil for neonates with persistent pulmonary hypertension of newborn (PPHN): a prospective study in a tertiary care hospital. <i>J Matern Fetal Neonatal Med</i>. Published online May 12, 2021. doi:10.1080/14767058.2021.1923003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/33980104/pubmed" id="33980104" target="_blank">33980104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30660783">
<a name="30660783"></a>Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. <i>Chest</i>. 2019;155(3):565-586. doi:10.1016/j.chest.2018.11.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/30660783/pubmed" id="30660783" target="_blank">30660783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15593188">
<a name="15593188"></a>Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. <i>Arthritis Rheum</i>. 2004;50(12):3985-3993.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/15593188/pubmed" id="15593188" target="_blank">15593188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941129">
<a name="27941129"></a>Kowal-Bielecka O, Fransen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Ann Rheum Dis.</i> 2017;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/27941129/pubmed" id="27941129" target="_blank">27941129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16919008">
<a name="16919008"></a>Lunze K, Gilbert N, Mebus S, et al, "First Experience With an Oral Combination Therapy Using Bosentan and Sildenafil for Pulmonary Arterial Hypertension," <i>Eur J Clin Invest</i>, 2006, 36 Suppl 3:32-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/16919008/pubmed" id="16919008" target="_blank">16919008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16216850">
<a name="16216850"></a>Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. <i>Heart.</i> 2006;92(5):664-670.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/16216850/pubmed" id="16216850" target="_blank">16216850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20805294">
<a name="20805294"></a>Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. <i>Ann Rheum Dis</i>. 2011;70(1):32-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/20805294/pubmed" id="20805294" target="_blank">20805294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19389575">
<a name="19389575"></a>McLaughlin VV, Archer SL, Badesch DB, et al, “ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration with the American College of Chest Physicians, American Thoracic Society, Inc, and the Pulmonary Hypertension Association,” <i>J Am Coll Cardiol</i>, 2009, 53(11):1573-619.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/19389575/pubmed" id="19389575" target="_blank">19389575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22076415">
<a name="22076415"></a>Mohamed WA, Ismail M. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn. <i>J Perinatol</i>. 2012;32(8):608-613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/22076415/pubmed" id="22076415" target="_blank">22076415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17116656">
<a name="17116656"></a>Moore TL, Vail A, Herrick AL. Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon. <i>Rheumatology (Oxford)</i>. 2007;46(2):363-364.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/17116656/pubmed" id="17116656" target="_blank">17116656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19523174">
<a name="19523174"></a>Nakwan N, Choksuchat D, Saksawad R, et al, "Successful Treatment of Persistent Pulmonary Hypertension of the Newborn With Bosentan," <i>Acta Paediatr</i>, 2009, 98(10):1683-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/19523174/pubmed" id="19523174" target="_blank">19523174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20040526">
<a name="20040526"></a>Nguyen VA, Eisendle K, Gruber I, Hugl B, Reider D, Redier N. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. <i>Rheumatology (Oxford)</i>. 2010;49(3):583-587.[<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/20040526/pubmed" id="20040526" target="_blank">20040526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69. doi: 10.1161/CIR.0000000000000426.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21380943">
<a name="21380943"></a>Radicioni M, Bruni A, Camerini P. Combination therapy for life-threatening pulmonary hypertension in a premature infant: first report on bosentan use. <i>Eur J Pediatr</i>. 2011;170(8):1075-1078.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/21380943/pubmed" id="21380943" target="_blank">21380943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16098438">
<a name="16098438"></a>Rosenzweig EB, Ivy DD, Widlitz A, et al, “Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension,” <i>J Am Coll Cardiol</i>, 2005, 46(4):697-704.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/16098438/pubmed" id="16098438" target="_blank">16098438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16919007">
<a name="16919007"></a>Sitbon O, Beghetti M, Petit J, et al, "Bosentan for the Treatment of Pulmonary Arterial Hypertension Associated With Congenital Heart Defects," <i>Eur J Clin Invest</i>, 2006, 36(Suppl 3):25-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/16919007/pubmed" id="16919007" target="_blank">16919007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27502103">
<a name="27502103"></a>Steinhorn RH, Fineman J, Kusic-Pajic A, et al. Bosentan as adjunctive therapy for persistent pulmonary hypertension of the newborn: results of the randomized multicenter placebo-controlled exploratory trial. <i>J Pediatr</i>. 2016;177:90-96.e3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/27502103/pubmed" id="27502103" target="_blank">27502103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24937180">
<a name="24937180"></a>Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. <i>Chest</i>. 2014;146(2):449-475. doi: 10.1378/chest.14-0793.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/24937180/pubmed" id="24937180" target="_blank">24937180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tracleer.1">
<a name="Tracleer.1"></a>Tracleer (bosentan) [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US Inc; June 2023.</div>
</li>
<li>
<div class="reference">
                  Tracleer (bosentan) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Niosh.1">
<a name="Niosh.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed September 8, 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 13087 Version 367.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
